News – Spirea

NEWS

Spirea wins Innovate UK grant to advance next-generation ADC technology

Spirea announces the promotion of Dr Ludovic Juen to Principal Scientist as the company continues to advance its proprietary technology in next-generation ADCs

Spirea welcomes Dr Bo Rode Hansen as Executive Director as the company further strengthens its management and business capabilities

Spirea featured by Cambridge Judge Business School

Dr Myriam Ouberai shortlisted for Woman Entrepreneur of the Year 2024

Spirea at the World ADC Conference in San Diego

Spirea presents its antibody drug conjugate technology at BioEquity 2023

Spirea presents its antibody drug conjugate technology at AACR 2023 in Orlando, Florida

Spirea included as one of the winners at the #21toWatch awards 2023

Spirea appoints Scientific Advisory Board of international ADC experts

Spirea is delighted to announce the appointment of Dr Ludovic Juen as a full-time senior scientist in drug discovery

Spirea granted UK patent on its high drug-to-antibody ratio ADC platform technology

Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer

Spirea secures further financing to develop the next generation of antibody drug conjugate therapeutics and validates platform technology

Spirea completes seed funding round to develop the next generation of antibody drug conjugate therapeutics

Start Codon showcases the first cohort of companies from its life science business acceleration programme

Spirea Ltd receives pre-seed funding from the University of Cambridge Enterprise Seed Funds

Dr Myriam Ouberai selected as a BioBusiness Mover and Shaker

Spirea Ltd receives pre-seed funding from IP Group

Spirea awarded grant by Innovate UK and matched pre-seed funding from IP Group